Understanding Australian Pharmacists' Perceptions on the Utilisation of Oral 5-HT3 Antagonists as Pharmacist-Only Anti-Emetics in Comparison to Oral D2 Antagonists.
J Pharm Pract
; 37(5): 1044-1047, 2024 Oct.
Article
en En
| MEDLINE
| ID: mdl-38380631
ABSTRACT
Objectives:
To investigate the perception of community pharmacists on the down-scheduling of 5-HT3 antagonists to pharmacist-only-medicine for treatment of acute nausea and/or vomiting in Australia.Methods:
A nationwide anonymous survey targeting Australian community pharmacists was conducted from April to May 2023. Responses were collected and analysed quantitively or qualitatively, where appropriate. Keyfindings:
Participants reported that 5-HT3 antagonists were effective at treating nausea and/or vomiting and would likely recommend their use. Training is required to manage supply due to concerns related to their side effects.Conclusion:
Participants supported down-scheduling of 5-HT3 antagonists for the treatment of nausea and/or vomiting in Australia. A pilot study on the provision of 5-HT3 antagonists by pharmacists is recommended as is the development of guidelines for pharmacist-only supply before down-scheduling is considered.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Farmacéuticos
/
Antagonistas del Receptor de Serotonina 5-HT3
/
Antieméticos
País/Región como asunto:
Oceania
Idioma:
En
Revista:
J Pharm Pract
Asunto de la revista:
FARMACIA
Año:
2024
Tipo del documento:
Article